People · Operator
Named in public records as an officer, director or promoter · active 2019–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.3M | 2020 |
| Edgewise Therapeutics, Inc. | — | Biotechnology | Series C | $120.1M | $3.3B | 2019 |
| Aristea Therapeutics, Inc. | — | Biotechnology | Series C | $63.1M | $2.3B | 2020 |
| Claris Biotherapeutics, Inc. | — | Biotechnology | Series C | $60.1M | $13.0M | 2020 |
Kenneth Harrison at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Harrison on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 1 | 16 |
| Peter Thompson | 1 | 16 |
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Niall O'Donnell | 1 | 7 |
| Meredith Fisher | 1 | 6 |
| Scott Weiner | 1 | 4 |
| James Mackay | 1 | 4 |
| Reza Dana | 1 | 3 |
| Art Pappas | 1 | 3 |
| Edward T. Mathers | 1 | 3 |
| Marc De Garidel | 1 | 3 |
| Bali Muralidhar | 1 | 3 |
| KEVIN KOCH | 1 | 3 |
| Michael G. Grey | 1 | 2 |
| R. Michael Carruthers | 1 | 2 |
| Clarke Atwell | 1 | 2 |
| Ciara Kennedy | 1 | 2 |
| Gregory Flesher | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.